Molecular Docking Estrogen Receptor Alpha Antagonist and P53- MDM2 Inhibitor, ADMET Prediction of Alkaloid Compound from Mitragyna speciosa for Breast Cancer Therapy
Pharmacognosy Journal · 10.01.2023 · 14 (6s) · 912-916
DOI: 10.5530/pj.2022.14.188 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacognosy Journal, online erschienen am 10.01.2023. Verfasst von Puja Adi Priatna und 3 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Priatna, P. A., Pratama, R. R., Widyowati, R., & Sukardiman, S. (2023). Molecular Docking Estrogen Receptor Alpha Antagonist and P53- MDM2 Inhibitor, ADMET Prediction of Alkaloid Compound from Mitragyna speciosa for Breast Cancer Therapy. Pharmacognosy Journal, 14(6s), 912-916. https://doi.org/10.5530/pj.2022.14.188
Vancouver
Priatna PA, Pratama RR, Widyowati R, Sukardiman S. Molecular Docking Estrogen Receptor Alpha Antagonist and P53- MDM2 Inhibitor, ADMET Prediction of Alkaloid Compound from Mitragyna speciosa for Breast Cancer Therapy. Pharmacognosy Journal. 2023;14(6s):912-916. doi:10.5530/pj.2022.14.188
BibTeX
@article{Priatna2023,
author = {Priatna, Puja Adi and Pratama, Rizki Rahmadi and Widyowati, Retno and Sukardiman, Sukardiman},
title = {Molecular Docking Estrogen Receptor Alpha Antagonist and P53- MDM2 Inhibitor, ADMET Prediction of Alkaloid Compound from Mitragyna speciosa for Breast Cancer Therapy},
journal = {Pharmacognosy Journal},
year = {2023},
volume = {14},
number = {6s},
pages = {912--916},
doi = {10.5530/pj.2022.14.188}
}
EUVIMED